CurrentColorado Rocky Mountain Health PlansPolicy N/A

Request for Neuromyelitis Optica Spectrum Disorder (NMOSD) therapy — Prior Authorization Form

This form governs prior authorization requests for medications to treat Neuromyelitis Optica Spectrum Disorder (NMOSD) for beneficiaries of Colorado Rocky Mountain Health Plans and captures beneficiary, prescriber, and drug-specific information plus clinical eligibility questions.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyRequest for Neuromyelitis Optica Spectrum Disorder (NMOSD) therapy — Prior Authorization Form

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit the completed prior authorization form with beneficiary, prescriber, drug details, clinical screening answers, and prescriber signature.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6clinical screening questions on form

5form sections

18+age criterion

Coverage and Eligibility Criteria

Initial therapy / Authorization criteria

Covered when ALL of the following are met (as indicated on the form):

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyRequest for Neuromyelitis Optica Spectrum Disorder (NMOSD) therapy — Prior Authorization Form

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit the completed prior authorization form with beneficiary, prescriber, drug details, clinical screening answers, and prescriber signature.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Implied exclusions: the form requires that the beneficiary meet specific clinical items and therefore does not meet coverage criteria if any of the required items are negative or not provided. Specifically, coverage is not supported for beneficiaries who are under 18 years of age, who are documented as AQP4 antibody negative, or who are currently receiving another injectable biologic immunomodulator. Additionally, failure to document consideration or screening for latent tuberculosis infection or testing for Hepatitis B surface antigen and core antibody would mean the request does not satisfy the form’s stated eligibility questions.

Provider Submission and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization required — submit a completed request form that includes beneficiary demographics, prescriber NPI and contact, requested drug name/strength/quantity/length of therapy, and answers to clinical screening questions for the indication.

Include beneficiary name, ID, DOB, and gender.
Prescriber NPI and requester contact name/phone (with ext.).
Drug name, strength, quantity per 30 days, and selected length of therapy.

Documentation Required

Verification of Current Biologic Therapy

Confirm the beneficiary is not currently receiving another injectable biologic immunomodulator prior to approval. The form must document that the patient is not on another injectable biologic immunomodulator.

Clinical screening question: “Is the beneficiary not on another injectable biologic immunomodulator?” — must be answered.
If the beneficiary is receiving another injectable biologic, provide clinical rationale for concurrent therapy or treatment change.

Denial Risk

Required Documentation and Missing Information / Signature Risk

Required documentation must be provided and the prescriber’s signature is mandatory. Incomplete requests, missing clinical screening answers, or an unsigned prescriber certification may result in denial or delay.

Completed beneficiary information (name, ID, DOB, gender).
Prescriber information including NPI and requester contact details.
Completed drug information (name, strength, quantity, length of therapy selection).
All clinical screening questions answered (diagnosis, AQP4 antibody status, age, TB and Hep B screening).
Prescriber signature and date — (Prescriber Signature Mandatory).

Step	Requirement
1
Beneficiary is not on another injectable biologic immunomodulator (form asks: "Is the beneficiary not on another injectable biologic immunomodulator?" with Yes/No response).

Key Definitions

anti-aquaporin-4 (AQP4) antibody positive — definition/flag captured on form

DefinitionAnti-aquaporin-4 (AQP4) antibody positive — as captured on the NMOSD prior authorization form by the clinician's affirmative response to 'Is the beneficiary anti-aquaporin-4 (AQP4) antibody positive?'

Form locationQuestion 2 on the NMOSD request form asks explicitly whether the beneficiary is AQP4 antibody positive (Yes/No).

Role in eligibilityA positive AQP4 antibody result is a required item in the form-based coverage criteria for NMOSD initial therapy (one of the ALL criteria to be met).

Documentation requirementThe provider must indicate AQP4 antibody positivity on the completed form submitted for prior authorization; missing or unanswered status may risk denial.

Implication of negative resultAn AQP4 antibody negative response implies the beneficiary does not meet this specific form criterion (an implied exclusion per the form).

Background

Neuromyelitis Optica Spectrum Disorder (NMOSD) is queried on the form as the indication for therapy. The document frames NMOSD as an autoimmune demyelinating condition identified by clinical diagnosis and often associated with anti-aquaporin-4 (AQP4) antibody positivity. Because disease-modifying biologic therapies are used for NMOSD, the form also captures standard pre-treatment infection screening (latent tuberculosis and Hepatitis B) prior to initiating immunomodulatory biologic therapy.

OpenPayer

Request for Neuromyelitis Optica Spectrum Disorder (NMOSD) therapy — Prior Authorization Form

Coverage and Eligibility Criteria

Provider Submission and Documentation Requirements

Initial Authorization Requirements

Step Therapy / Concomitant Biologics

Key Definitions

Background